JBIO · CIK 0001798749 · operating
# Jade Biosciences, Inc.
Jade Biosciences is a biotechnology company headquartered in Waltham, Massachusetts, focused on developing therapies for inflammation and immunology indications in patients with autoimmune diseases. The company's lead candidate, JADE101, is a monoclonal antibody designed to block A PRoliferation Inducing Ligand (APRIL) protein and is currently in phase 1 clinical development. The company also maintains two preclinical-stage programs: JADE201 and JADE-003.
The company operates with approximately 30 full-time employees and is incorporated in Delaware with listing on the Nasdaq. Jade Biosciences has established a collaboration agreement with Paragon Therapeutics, Inc. to advance its pipeline. As a clinical-stage biotechnology company, the firm does not currently generate meaningful product revenues and instead relies on capital funding to support research and development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.44 | $-2.44 | +15.0% | |
| 2023 | $-2.87 | $-2.87 | -36.7% | |
| 2022 | $-2.10 | $-2.10 | — | |
| 2021 | — | — | — |